Skip Navigation

European Heart Journal 2003 24(2):198-208; doi:10.1016/S0195-668X(02)00385-8
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Glader, C.A
Right arrow Articles by Dahlén, G.H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glader, C.A
Right arrow Articles by Dahlén, G.H
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis

C.A Gladera,*, L.S Birganderb, S Söderbergb, H.P Ildgrubenc, P Saikkud, A Waldenströmb and G.H Dahléna

a Department of Medical Biosciences, Clinical Chemistry, Umeå University, Sweden
b Department of Public Health and Clinical Medicine, Umeå University, Sweden
c Department of Surgical and Perioperative Sciences, Umeå University, Sweden
d Department of Medical Microbiology, University of Oulu, Finland

Received March 19, 2002; accepted May 29, 2002 * Correspondence: Christine Ahlbeck Glader, MD, PhD, TheAthrosclerosis Research Unit, King Gustaf V Research Institute, Karolinska Hospital, SE-171 76 Stockholm, Sweden

Aims The aim of the present study was to identify risk markers for the development of valvular aortic stenosis (AS). Lipoprotein(a) (Lp(a)) and Chlamydia pneumoniae IgG antibody titres in plasma and in circulating immune complexes as well as leptin and tissue plasminogen activator (t-PA) in plasma were studied.

Methods and Results One hundred and one patients (41 women and 60 men, mean age 71±8 years) with significant AS and 101 age- and sex-matched controls were included in this study. All patients underwent aortic valve replacement at the University Hospital in Ume, Sweden. The controls had no symptoms of cardiovascular disease and they were examined echocardiographically. An Lp(a) level ≥480 mg.l–1, a C. pneumoniae-specific IgG titre ≥1/128, a high leptin level and a high t-PA mass concentration in plasma were identified as risk markers for AS. A strong synergism between Lp(a) and C. pneumoniae IgG antibodies in circulating immune complexes was found.

Conclusion Our data indicate that a chronic C. pneumoniae infection and a high plasma Lp(a) level might influence and aggravate aortic heart valve sclerosis via the formation of circulating immune complexes. The present study also strongly suggests an association between high plasma leptin, t-PA mass concentration and AS.

Key Words: Lipoprotein(a) • valvular aortic stenosis • chlamydia pneumoniae • circulating immune complexes • leptin • tissue plasminogen activator


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Aortic stenosis
P Zarco
EHJ 2003 24: 133-135. [Extract] [Full Text]  



This article has been cited by other articles:


Home page
 BMJHome page
R. Ramaraj and V. L Sorrell
Degenerative aortic stenosis
BMJ, March 8, 2008; 336(7643): 550 - 555.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
D. Skowasch, S. Schrempf, N. Wernert, M. Steinmetz, A. Jabs, I. Tuleta, U. Welsch, C. J. Preusse, J. A. Likungu, A. Welz, et al.
Cells of primarily extravalvular origin in degenerative aortic valves and bioprostheses
Eur. Heart J., December 1, 2005; 26(23): 2576 - 2580.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. H. Rahimtoola
The year in valvular heart disease
J. Am. Coll. Cardiol., February 4, 2004; 43(3): 491 - 504.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
P Zarco
Aortic stenosis
Eur. Heart J., January 2, 2003; 24(2): 133 - 135.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.